Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (CRSP) to Neutral from Overweight, citing potential barriers and lower than consensus sales estimates for its sickle cell therapy, exa-cel, developed in partnership with Vertex Pharmaceuticals Inc (VRTX). Despite this, the analyst expects a positive recommendation for exa-cel due to its favorable benefit-risk profile. CRSP's stock performance is expected to be closely tied to its product lineup as gene editing technology becomes more common.
October 17, 2023 | 6:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Vertex Pharmaceuticals is mentioned as the partner of CRISPR Therapeutics in the development of the sickle cell therapy, exa-cel.
Vertex Pharmaceuticals is mentioned as the partner of CRISPR Therapeutics in the development of the sickle cell therapy, exa-cel. However, the news does not directly impact Vertex's stock.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
CRISPR Therapeutics has been downgraded by Cantor Fitzgerald due to potential barriers and lower than consensus sales estimates for its sickle cell therapy, exa-cel.
The downgrade by Cantor Fitzgerald is based on potential barriers and lower than consensus sales estimates for its sickle cell therapy, exa-cel. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100